Trial Profile

A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Isatuximab (Primary) ; Dexamethasone; Dexamethasone
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

01 May 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
01 May 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
06 Dec 2024 According to a Kymera Therapeutics media release, the John Theurer Cancer Center Researchers to present data from this trial at the 66th Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, California, from December 7-10, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com